Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
2
100%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(1)
Other(1)

Detailed Status

unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

unknown150%
withdrawn150%

Recent Activity

0 active trials
Showing 2 of 2
withdrawnphase_2

Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

NCT05482334
unknownphase_2

Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

NCT05075122

Clinical Trials (2)

Showing 2 of 2 trials
NCT05482334Phase 2

Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

Withdrawn
NCT05075122Phase 2

Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2